热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE anti-human CD279 (PD-1) Antibody
产品名称：
PE anti-human CD279 (PD-1) Antibody
产品类别：
抗体
产品编号：
329906
产品应用：
329906
[价格]
规格 价格 库存
100tests ￥ 3504 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The CD279 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
SB -?Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3,?immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
  16. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
Product Citations
  1. Shaw BI, et al. 2021. J Immunol. 206:1668. PubMed
  2. Li M, et al. 2021. J Clin Invest. 131:. PubMed
  3. Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed
  4. Fujita T, et al. 2014. J Immunol. 193:5576. PubMed
  5. Chang W, et al. 2008. J Immunol. 181:6707. PubMed
  6. Wang F, et al. 2018. Oncogenesis. 7:41. PubMed
  7. Jung MY, et al. 2022. Neurooncol Adv. 4:vdac017. PubMed
  8. Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed
  9. Rha MS, et al. 2021. Immunity. 54:44. PubMed
  10. Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed
  11. Diao B, et al. 2020. Front Immunol. 1.032638889. PubMed
  12. Huang L, et al. 2018. Mol Med Rep. 18:77. PubMed
  13. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  14. Swadling L, et al. 2020. Cell Rep. 30:687. PubMed
  15. Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed
  16. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  17. Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed
  18. Lucas C, et al. 2020. Nature. 584:463. PubMed
  19. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  20. Gao Y, et al. 2021. Oncogenesis. 10:62. PubMed
  21. Minns D, et al. 2021. Front Immunol. 12:633486. PubMed
  22. Zhu C, et al. 2012. J Clin Endocrinol Metab. 97:943. PubMed
  23. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  24. Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed
  25. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  26. Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed
  27. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  28. Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed
  29. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  30. Pauthner M et al. 2017. Immunity. 46(6):1073-1088 . PubMed
  31. Suzuki M, et al. 2012. J Immunol. 189:2118. PubMed
  32. Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed
  33. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  34. Raghuraman S, et al. 2012. J Infect Dis. 205:763. PubMed
  35. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  36. Alishah K, et al. 2021. J Transl Med. 19:482. PubMed
  37. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  38. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  39. Shen C, et al. 2021. Front Immunol. 12:680055. PubMed
  40. Song TZ, et al. 2021. Front Endocrinol (Lausanne). 12:745984. PubMed
  41. Chen W, et al. 2021. MAbs. 13:1914359. PubMed
  42. Vikkurthi R, et al. 2022. Nat Microbiol. 7:974. PubMed
  43. OConnor RA, et al. 2021. OncoImmunology. 10(1):1940675. PubMed
  44. Colineau L, et al. 2015. PLoS One. 10: e0140978. PubMed
  45. Wang C, et al. 2020. Oncologist. 25:382. PubMed
  46. Chen Y, et al. 2022. Bioact Mater. 9:251. PubMed
  47. Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed
  48. Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed
  49. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  50. Li N, et al. 2020. Oncoimmunology. 9:1824643. PubMed
  51. Kamiya T, et al. 2018. Blood Adv. 2:517. PubMed
  52. Good Z, et al. 2019. Nat Biotechnol. 37:259. PubMed
  53. Ling X, et al. 2022. STAR Protoc. 3:101321. PubMed
  54. Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed
  55. Pombo C, et al. 2015. J Infect Dis. 12: 1376-1386. PubMed
  56. Shuwa HA, et al. 2021. Med. 2(6):720-735.e4. PubMed
  57. Radziewicz H, et al. 2010. J Immunol. 184:2410. PubMed
  58. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  59. Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed
  60. Toor SM, et al. 2021. Vaccines (Basel). 9:. PubMed
  61. Xu Y, et al. 2013. J Virol. 87:3760. PubMed
  62. Richter M, et al. 2016. Mol Ther Methods Clin Dev. 5:16013. PubMed
  63. Matsuyama H, et al. 2019. Sci Rep. 9:13181. PubMed
  64. Eriksen LL, et al. 2021. PLoS One. 16:e0255574. PubMed
  65. Zheng L, et al. 2020. Clin Cancer Res. 26:3694. PubMed
  66. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  67. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  68. Ukita M, et al. 2022. JCI Insight. 7:. PubMed
  69. Wadley AJ, et al. 2020. Brain Behav Immun Health. 3:100049. PubMed
  70. Vojnov L, et al. 2010. J Virol. 84:753. PubMed
  71. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  72. Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed
  73. Schumann K, et al. 2015. Proc Natl Acad Sci U S A. 112: 10437-10442. PubMed
  74. Li B, et al. 2019. Oncogenesis. 8:17. PubMed
  75. Cortés–Rubio CN, et al. 2019. Clin Epigenetics. 11:134. PubMed
  76. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
RRID
AB_940481 (BioLegend Cat. No. 329905) AB_940483 (BioLegend Cat. No. 329906)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线